Castle Biosciences

139 articles with Castle Biosciences

• Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients With Thin Cutaneous Melanoma Tumors

  7/11/2019

  Study published recently in SKIN: The Journal of Cutaneous Medicine

• Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma

  6/6/2019

  Poster presentation at 2019 Fall Clinical Dermatology Conference for PAs & NPs

• Prospective, Multicenter Study of DecisionDx-Melanoma Supports Accuracy and Performance in Prediction of Cutaneous Melanoma Outcomes

  6/4/2019

  Results from cohort with median follow up of 3.2 years presented at 2019 ASCO Annual Meeting

• Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Update Presented at the American College of Mohs Surgery Annual Meeting

  5/7/2019

  Also presented were results from a meta-analysis of DecisionDx-Melanoma in 1,479 patients which provides the highest level of evidence (1A) as an independent, significant predictor of risk in cutaneous melanoma

• American Cancer Society's Newly Formed Philanthropic Impact Fund Makes First Investment

  4/18/2019

  Convertible note financing of Castle Biosciences, an innovator in skin-cancer diagnostics, is first investment for BrightEdge

• Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma

  4/11/2019

  Results published in Cancer Medicine are consistent with previously published prospective and retrospective studies

• Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test

  3/25/2019

  Data presented at International Society of Ocular Oncology (ISOO) 2019 Conference

• Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

  2/7/2019

  Castle Biosciences, Inc. announced the publication of a study highlighting the ability of the DecisionDx®-Melanoma test to accurately determine risk of metastasis in patients with melanoma of the head and neck.

• Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

  1/30/2019

  Validation data from 1,421 patients published in Future Oncology

• Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

  1/7/2019

  Results from this cumulative validation study are consistent with prior multicenter and single-center, independent prospective studies

• Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to Its Board of Directors

  12/6/2018

  Castle Biosciences, Inc. today announced the appointment of G. Bradley Cole to its Board of Directors.

• Castle Biosciences to Present at the 2018 Piper Jaffray Healthcare Conference

  11/21/2018

  Castle Biosciences, Inc. today announced that Derek Maetzold, President and CEO, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28th, 2018 at 10:10 a.m. EST in New York City.

• Study Demonstrating Accuracy of DecisionDx-Melanoma Prognostic Test Across Melanoma Tissue Sources Presented at the American Society of Dermatopathology 55th Annual Meeting

  11/13/2018

  Castle Biosciences, Inc. today announced study results showing that the DecisionDx-Melanoma test accurately predicts risk for patients with cutaneous melanoma when using either biopsy or wide local excision (WLE) as the tissue source.

• Castle Biosciences to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

  11/8/2018

  Castle Biosciences, Inc. today announced that Derek Maetzold will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum.

• Study Demonstrates DecisionDx-Melanoma Prognostic Test Accuracy in Patients with Stage II-IIIA Melanoma

  10/30/2018

  Data at the Society for Melanoma Research 2018 Congress highlights benefits of prognostic testing for adjuvant therapy clinical trial designs

• Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

  10/18/2018

  Palmetto GBA issues final local coverage determination effective December 3, 2018

• Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Progress Highlighted in Oral Presentation at American Society for Dermatologic Surgery Annual Meeting

  10/17/2018

  Aaron Farberg, M.D., Icahn School of Medicine at Mount Sinai, New York, presented the study last week during the Reconstructive, Skin Cancer and Mohs Micrographic Surgery session of the 2018 American Society for Dermatologic Surgery Annual Meeting held in Phoenix.

• Castle Biosciences to Present at the Baird 2018 Global Healthcare Conference

  8/30/2018

  Castle Biosciences, Inc. today announced that Derek Maetzold, President and CEO, will present at the Baird Global Healthcare Conference on Wednesday, September 5th, 2018 at 11:25 a.m. ET in New York City.

• Newly Published Independent Study on a Prospective Cohort Highlights DecisionDx-Melanoma Prognostic Test’s Ability to Accurately Identify High-Risk Melanoma Patients

  8/9/2018

  Results from this second prospective study are consistent with prior four clinical validation studies

• Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

  7/30/2018

  Test demonstrated high technical reliability in over 17,000 clinical orders